摘要随着各种微透镜近视离焦设计镜片出现，评估和验证其近视控制效果并把控其质量和配戴安全性，逐步引起广泛关注。目前我国尚未将近视防控框架眼镜归为受国家相关部门直接监管的医疗器械。微透镜近视离焦设计镜片框架眼镜作为延缓近视进展的重要方法之一，尤其对于儿童青少年配戴者，更应保证近视控制的有效性和配戴安全性，并规范验配流程。为此，中国健康管理协会接触镜安全监控与视觉健康专业委员会和四川省视光学学会西部视光学专家委员会基于目前的循证医学证据，并结合实践经验，在广泛征求意见的基础上，针对多点微透镜近视离焦设计镜片的质量控制、有效性评价（包括长期有效性）、安全性评价及其框架眼镜验配服务规范达成共识性意见，以期为相关机构和从业人员开展工作提供指导和参考。

abstractsWith the emergence of various multi-segment myopic defocus design spectacles, evaluating and verifying their myopia control effectiveness and controlling their quality and wearing safety have gradually attracted widespread attention. At present, myopia prevention and control spectacles have not been classified as medical devices directly supervised by relevant national departments in China. Multi-segment myopic defocus design spectacles, as an important intervention for retarding the progression of myopia, especially for children and adolescents, should ensure the myopia control effectiveness, safety, and adherence to standardized fitting protocols. Aiming to provide guidance and reference for healthcare institutions and practitioners, the Society of Contact Lens Safety Monitoring & Vision Health of Chinese Health Association and the Western Optometry Expert Committee of Sichuan Optometry Society, based on the current evidence-based medical research, combined with practical experience and extensive solicitation of opinions, have reached consensus opinions on the quality control, effectiveness evaluation (including long-term effectiveness), and safety evaluation of multi-segment myopic defocus design spectacles, as well as the service norms for the fitting of spectacles.